Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib Assessment in Refractory Advanced Colorectal Cancer
2012-005655-16Phase 2Completed
- Sponsor
- Institut Jules Bordet
- Start
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of regorafenib in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC), sponsored by Institut Jules Bordet. Primary endpoint: Overall survival. Started May 2013; status: completed.
02
Drugs
regorafenib
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2012-005655-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005655-16.